Proteins and Peptides
28 September 2015
Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting28 September 2015
Aeterna Zentaris’ Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer24 September 2015
FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome22 September 2015
Blaze Bioscience Commences Clinical Trial of BLZ-100 in Patients with Sarcoma Undergoing Surgery22 September 2015
Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction21 September 2015
RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-25917 September 2015
Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome16 September 2015
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes16 September 2015
Intarcia Presents Results From Two Successful Phase 3 Trials For ITCA 650, Its Investigational Therapy In Type 2 Diabetes, At 51st EASD16 September 2015
Victoza® (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial15 September 2015
Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting15 September 2015
Pieris Pharmaceuticals’ Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin Program at ASM Conference15 September 2015
FDA Approves Octapharma’s NUWIQ® for the Treatment of Adults and Children with Hemophilia A14 September 2015
Aeglea BioTherapeutics Announces FDA Acceptance of Investigational New Drug Application for AEB110211 September 2015
Versartis Initiates Phase 2 Trial (VITAL) of Monthly Somavaratan in Adults With Growth Hormone Deficiency10 September 2015
Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes10 September 2015
Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis8 September 2015
Generex Announces Commencement of Buccal Leuprolide R&D Work8 September 2015
Promedior Announces Initiation of a Phase 2 Clinical Study of PRM-151 in Idiopathic Pulmonary Fibrosis (IPF)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports